PP
RYTM icon

PDT Partners’s Rhythm Pharmaceuticals RYTM Stock Holding History

PDT Partners’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.37M Sell
27,232
-32,204
-54% -$3.13M 0.14% 220
2025
Q4 		$6.36M Sell
59,436
-26,700
-31% -$2.83M 0.41% 61
2025
Q3 		$8.7M Sell
86,136
-11,502
-12% -$1.07M 0.55% 34
2025
Q2 		$6.17M Sell
97,638
-4,557
-4% -$279K 0.35% 67
2025
Q1 		$5.41M Buy
102,195
+58,612
+134% +$3.25M 0.38% 57
2024
Q4 		$2.44M Buy
43,583
+32,083
+279% +$1.77M 0.22% 160
2024
Q3 		$602K Sell
11,500
-10
-0.1% -$479 0.05% 466
2024
Q2 		$473K Buy
+11,510
New +$459K 0.04% 475
2018
Q4 		– Sell
-17,207
Closed -$502K – 505
2018
Q3 		$502K Sell
17,207
-22,193
-56% -$701K 0.02% 361
2018
Q2 		$1.23M Buy
39,400
+1,693
+4% +$46.3K 0.05% 306
2018
Q1 		$750K Buy
+37,707
New +$1M 0.03% 394

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

PDT Partners's RYTM Position: Q1 2026 in Review

PDT Partners reduced its Rhythm Pharmaceuticals (RYTM) stake by 54% in Q1 2026, selling an estimated $3.13M and leaving 27,232 shares worth $2.37M. The position accounts for 0.14% of the portfolio, ranked #220.

PDT Partners first reported a position in RYTM in Q1 2018 and has held it in 11 quarters since. The position peaked at $8.7M in Q3 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • PDT Partners held 27,232 shares of Rhythm Pharmaceuticals worth $2.37M as of Q1 2026.
  • PDT Partners sold 32,204 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $3.13M.
  • Rhythm Pharmaceuticals made up 0.14% of PDT Partners's portfolio in Q1 2026, its #220 holding.
  • PDT Partners first reported a position in Rhythm Pharmaceuticals in Q1 2018 and has held it in 11 quarters since.
  • PDT Partners's Rhythm Pharmaceuticals position peaked at $8.7M in Q3 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on PDT Partners's 13F filing for Q1 2026, filed 15 May 2026.